Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

2 hours ago 5

Jonathan Ponciano, The Motley Fool

Mon, May 18, 2026 astatine 12:33 PM CDT 4 min read

Octagon Capital Advisors chopped its involvement successful Dianthus Therapeutics (NASDAQ:DNTH) by 470,000 shares, an estimated $27.22 cardinal commercialized based connected quarterly mean pricing, according to a May 15, 2026 SEC filing.

What happened

According to a SEC filing dated May 15, 2026, Octagon Capital Advisors reduced its holding successful Dianthus Therapeutics by 470,000 shares during the archetypal quarter. The estimated worth of the shares sold was $27.22 million, based connected the mean closing terms for the quarter. The quarter-end worth of the remaining involvement roseate by $63.77 million, a alteration reflecting some stock income and banal terms appreciation.

What other to cognize

Octagon Capital Advisors’ post-sale involvement successful Dianthus Therapeutics represents 18.08% of its 13F assets nether management
Top holdings aft the filing:
- NASDAQ: DNTH: $163.36 cardinal (18.1% of AUM)
- NASDAQ:COGT: $90.45 cardinal (10.0% of AUM)
- NASDAQ:ABVX: $75.38 cardinal (8.3% of AUM)
- NASDAQ:ALMS: $62.36 cardinal (6.9% of AUM)
- NASDAQ:DFTX: $46.12 cardinal (5.1% of AUM)
As of May 14, 2026, shares of Dianthus Therapeutics were priced astatine $85.34, up astir 320% implicit the past year, compared to a 25% summation from the S&P 500.

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-14)	$85.34
Market Capitalization	$4 billion
Revenue (TTM)	$2 million
Net Income (TTM)	($162.3 million)

Company Snapshot

Dianthus Therapeutics develops caller monoclonal antibody therapies targeting terrible autoimmune and inflammatory diseases.
The steadfast operates a clinical-stage biotechnology concern exemplary focused connected the probe and improvement of proprietary biologic cause candidates.
It serves patients with terrible autoimmune and inflammatory disorders.

Dianthus Therapeutics, Inc. is simply a clinical-stage biotechnology institution based successful New York City, specializing successful the improvement of monoclonal antibody therapies for terrible immune-mediated diseases. The institution leverages proprietary probe to beforehand its pipeline, aiming to code unmet aesculapian needs successful neuromuscular and inflammatory conditions.

What this transaction means for investors

Even aft trimming 470,000 shares, Dianthus inactive remained Octagon Capital Advisors’ largest disclosed presumption astatine much than 18% of 13F assets, which says a batch astir the fund’s condemnation successful the company’s semipermanent autoimmune pipeline.

The bigger communicative is that Dianthus keeps hitting operational milestones Earlier this month, absorption said it reached an aboriginal “GO” determination successful its Phase 3 CAPTIVATE proceedings aft identifying 20 confirmed responders earlier adjacent reaching the planned 40-patient threshold. The institution besides said its generalized myasthenia gravis Phase 3 survey remains connected way to statesman successful mid-2026, with top-line results expected successful the 2nd fractional of 2028.

Financially, Dianthus appears well-capitalized. The institution exited March with astir $1.2 cardinal successful currency and investments, capable runway into 2030, aft raising astir $719 cardinal successful a nationalist offering earlier this year. The cardinal question present is whether Dianthus tin construe promising aboriginal efficacy into late-stage occurrence earlier contention successful autoimmune biologics intensifies.

Read Entire Article